Dexlansoprazole

Quick links to important sections

Dexlansoprazole

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dexlansoprazole

Property Description
Active ingredient Dexlansoprazole
Form Delayed-release capsules (Dual Delayed-Release, DDR)
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Suppression of gastric acid secretion
Origin Synthetic (R-enantiomer of Lansoprazole)

Dexlansoprazole: Pharmacological Identity and Origin

Dexlansoprazole is a prescription-only medication that belongs to the Proton Pump Inhibitor (PPI) pharmacological class, clinically recognized for its role in the suppression of gastric acid secretion. This pharmaceutical compound is synthetic in origin and is chemically recognized as a substituted benzimidazole derivative. It is the pure, active R-enantiomer isolated from the older drug Lansoprazole, a structural modification known as a chiral switch. Pharmacological studies confirm that Dexlansoprazole is an effective inhibitor of the hydrogen-potassium ATPase enzyme system. As a single-active ingredient product, its fundamental purpose is to address chronic acid-related gastrointestinal conditions.


What is the Dual Delayed-Release (DDR) Formulation?

The product is uniquely presented for oral administration as delayed-release capsules, which utilize a specialized technology called the dual delayed-release (DDR) formulation. This is a differentiating factor because this sophisticated pharmaceutical preparation contains the active ingredient in two distinct types of enteric-coated granules within the same capsule. The DDR system is designed to release Dexlansoprazole at two separate times: an initial release soon after ingestion, followed by a second, separate release several hours later. The DDR formulation allows for a unique pharmacokinetic profile. This design is essential to the drug’s identity, aiming to maintain a more consistent and prolonged acid-blocking effect throughout the full 24-hour cycle.


General Purpose of Proton Pump Inhibition

The primary function of this medication is achieved through the mechanism of proton pump inhibition, resulting in the profound and sustained reduction of acid in the stomach. By acting on the final step of acid production, the medication prevents the severe acidity that drives many acid-related gastrointestinal conditions. A typical neutral use scenario involves reducing the frequent occurrence of heartburn associated with gastroesophageal reflux disease (GERD). The general purpose is to mitigate the corrosive impact of stomach acid, thereby alleviating associated symptoms and supporting the natural healing processes in the esophagus and stomach. This powerful acid reduction is the core benefit delivered by this pharmacological classification.

What side effects are possible with Dexlansoprazole?

Possible Side Effects and Safety Information

The safety profile for Dexlansoprazole, a substituted benzimidazole, is documented across several regulatory domains, classifying potential effects by frequency and the body system affected. All safety information is based strictly on government regulatory documents.

Frequency and System-Organ Classes

The most frequently reported adverse reactions observed in clinical trials are classified as Common and often involve the gastrointestinal and nervous systems, as noted in the official prescribing information. Examples include headache, diarrhea, abdominal pain, nausea, and flatulence. Less common adverse reactions, such as dizziness, rash, and joint pain (arthralgia), are also documented in regulatory sources.

Serious and Duration-Related Safety Patterns

The official label highlights several serious adverse reactions that have been associated with this class of medication, which may include severe cutaneous reactions like Stevens-Johnson syndrome (SJS), Acute Interstitial Nephritis (AIN), and severe electrolyte imbalance, specifically hypomagnesemia. Furthermore, a relationship is documented between high-dose or long-term use (typically one year or longer) and an increased risk of bone fractures of the hip, wrist, or spine. The development of benign fundic gland polyps is also noted as a condition associated with prolonged treatment.

Population-Specific Safety Notes

Safety constraints are specified for patients with existing conditions. Use is generally not recommended in individuals with severe hepatic impairment. A specific, reduced maximum daily dose is documented for consideration in patients with moderate hepatic impairment. The drug is also contraindicated in individuals with known hypersensitivity to the formulation or to any substituted benzimidazole compound.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation on dexlansoprazole over-exposure provides specific guidance based on clinical data and mandated emergency procedures.

Documented Overdose Manifestations

Regulatory authorities report a lack of significant overdose in humans to date. However, clinical trials using non-standard, high-dose regimens (up to 300 mg single doses) have documented adverse events, including the serious event of Hypertension.

Non-serious reactions associated with these higher-than-recommended doses included hot flashes, oropharyngeal pain, contusion, and weight loss. Overall, no deaths or severe adverse events were reported following these high-dose administrations.

Official Emergency Actions

In the event of suspected over-exposure or overdose, regulatory instructions require the individual to seek immediate medical attention by contacting a regional poison control center.

  • Treatment: Management is universally designated as symptomatic and supportive care. There is no specific antidote available for dexlansoprazole over-exposure, and the medication is not expected to be removable from circulation by hemodialysis, according to official labeling.

  • When to Seek Help: Urgent medical help is required immediately upon suspected over-exposure, and patients should follow the guidance of their local poison control center or emergency services.

Therapeutic Uses of Dexlansoprazole

Quick Facts

  • Management of Erosive Esophagitis (EE)
  • Maintenance of healed Erosive Esophagitis
  • Symptom relief for Gastroesophageal Reflux Disease (GERD) in individuals with non-erosive reflux disease

Dexlansoprazole is a prescription medication utilized to treat conditions related to excessive gastric acid production. The established therapeutic uses of the drug focus on two primary gastrointestinal disorders:

  1. Erosive Esophagitis (EE): This medication is indicated for the healing of all grades of EE, which involves damage to the lining of the esophagus due to acid exposure. Furthermore, it is used for the maintenance of healed EE and to provide relief from associated heartburn symptoms.
  2. Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD): Dexlansoprazole is prescribed for the short-term treatment of heartburn linked with non-erosive GERD, a chronic digestive disorder where the backward flow of stomach acid causes bothersome symptoms without significant esophageal tissue injury.

The benefit of this agent lies in its mechanism to reduce the amount of acid the stomach produces, which supports the healing process in the esophagus and alleviates symptoms of acid reflux.

Eligibility and Restrictions for Use

Who can and cannot use Dexlansoprazole?

Dexlansoprazole is regulated for use across specific patient populations, with eligibility established primarily for adults and adolescents aged 12 to 17 years for its approved indications.

Eligibility Status Population/Condition
Contraindicated Patients with known hypersensitivity to the drug or its components. Patients receiving rilpivirine-containing products concomitantly.
Use Not Recommended Patients with Severe Hepatic Impairment (Child-Pugh Class C). Children younger than 2 years of age.

Age and Condition Restrictions

Safety and efficacy have not been established in children younger than 12 years. For geriatric patients, no specific dose adjustment is necessary.

Use is subject to limitations in individuals with Moderate Hepatic Impairment (Child-Pugh Class B). Individuals with rare hereditary problems, such as fructose intolerance, are non-eligible due to the excipients in the formulation.

Pregnancy and Lactation

Due to the absence of adequate human data, use during pregnancy is classified as conditional, only permitted if clearly needed. During lactation, it is unknown if the drug is excreted into human milk, requiring a conditional assessment before use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify dexlansoprazole interactions primarily by two mechanisms: the alteration of gastric pH and metabolism via CYP2C19 and CYP3A4 enzymes.

Contraindicated and Restricted Combinations

Co-administration with Rilpivirine-containing products is formally contraindicated because the resulting decrease in acidity substantially reduces the antiretroviral's systemic exposure. The combination with other HIV antiretrovirals like Atazanavir and Nelfinavir is similarly not recommended due to the risk of reduced bioavailability. Strong enzyme inducers, including Rifampin and the herbal product St. John's Wort, are advised to be avoided as they can significantly decrease dexlansoprazole plasma concentrations.

Exposure-Modifying and Monitoring Required Interactions

Dexlansoprazole's acid-suppressing effect may lead to sub-therapeutic concentrations of medications like Ketoconazole and Itraconazole, whose absorption is pH-dependent. Conversely, it may increase the systemic exposure of other drugs, including Digoxin and Tacrolimus, which necessitates therapeutic drug monitoring. Concomitant use with Warfarin may cause increases in the International Normalized Ratio (INR) and prothrombin time, requiring official monitoring. Furthermore, Antacids and Sucralfate should be taken at least one hour after dexlansoprazole to prevent a decrease in its own absorption. In patients with moderate hepatic impairment, the medicine's clearance is slower, increasing exposure, and a maximum dose of 30 mg is considered for certain uses.

Mechanism of Action

Dexlansoprazole functions as a prodrug that is converted into its active sulfenamide metabolite within the acidic environment of the secretory canaliculi of gastric parietal cells. This active metabolite selectively and irreversibly targets the H^+/ K^+-ATPase enzyme, commonly known as the proton pump, which is embedded in the luminal membrane of these cells.

This interaction is characterized by the sulfenamide forming a covalent bond with specific cysteine residues on the extracellular domain of the proton pump. The covalent binding causes a conformational change that inactivates the enzyme. Because this binding is irreversible, it ensures that the enzyme is inactivated until new pump molecules are synthesized and inserted into the membrane. The resulting action is the inhibition of the final step of acid secretion, which is the translocation of H^+ ions into the stomach lumen in exchange for K^+ ions. This sustained blockage of the H^+/ K^+-ATPase activity modulates the gastric environment by reducing the total volume and concentration of secreted hydrochloric acid.

Dosage and Administration Information

How to Use Dexlansoprazole: Administration Guidelines

Dexlansoprazole is administered via the oral route as a specialized delayed-release capsule that utilizes a Dual Delayed-Release (DDR) technology. The administration method, required dosage, and duration are based on the treatment course. The capsule may be taken without regard to food and is integrated into a consistent once-daily schedule.

Dosing Regimens and Duration

Dosing is determined by the specific therapeutic goal and is based on a once-daily frequency pattern, with a specified maximum duration for acute use.

Indication Standard Dose Maximum Duration (Acute)
Healing of Erosive Esophagitis (EE) 60 mg once daily Up to 8 weeks
Maintenance of Healed EE 30 mg once daily Controlled studies up to 6 months
Symptomatic Non-Erosive GERD 30 mg once daily 4 weeks

Procedural Administration Constraints

To preserve the function of the DDR formulation, the capsule must be swallowed whole and should not be chewed or crushed. For patients unable to swallow the capsule, the contents may be opened and administered with one tablespoon of applesauce or mixed with water for delivery via an oral syringe or a nasogastric (NG) tube gauge 16 French. In all cases of alternative administration, the granules must not be crushed or chewed and should be swallowed immediately after preparation.

Population-Specific Rules

Use in pediatric patients aged 12 years and older follows the standard adult dosing regimens. Dose adjustments are required for impaired liver function: patients with moderate hepatic impairment (Child-Pugh Class B) should not exceed 30 mg once daily. No adjustment is necessary for renal impairment.

Recent Clinical Evidence

Dexlansoprazole: Recent Clinical Evidence

The evidence base for Dexlansoprazole is primarily built upon controlled scientific research, including Randomized Controlled Trials (RCTs). These studies were evaluated in research exploring outcomes related to conditions such as damage associated with acid reflux and symptom patterns related to acid-related disorders.


Evidence for Healing and Maintenance of Erosive Esophagitis (EE)

For the healing of Erosive Esophagitis (EE), large, double-blind RCTs were carried out, with the core outcome evaluated being the complete healing of esophageal erosions, which was confirmed via endoscopy over an 8-week period. Follow-up research then explored the maintenance of healed EE using longer-duration, placebo-controlled trials, typically with observation periods up to six months. Findings from this anatomical research structure are generally supported by a High level of evidence.


Evidence for Symptom Relief in Non-Erosive GERD (NERD)

Research for Symptom Relief in Non-Erosive GERD (NERD) focused on short-term, placebo-controlled RCTs, applied in studies examining patient-reported experiences over approximately four weeks. The outcomes monitored were patient-reported measures, such as the frequency of heartburn-free days and nights. Systematic reviews indicate that the overall structural certainty for these symptomatic endpoints remains moderate, often due to the limited trial duration and modest sample sizes across aggregated studies.


Research Gaps, Uncertainty, and Special Populations

Dedicated studies were evaluated in adolescents (ages 12 to 17 years) for healing, maintenance, and symptom relief. However, data for certain groups remain insufficient, particularly for children under 12 years of age, where research is ongoing. Furthermore, the highest-quality evidence is limited to intermediate observation periods, meaning long-term effects are not fully established. Comparative evidence exploring short-term symptom changes against certain comparators is also limited.

Key Studies & References

  1. Safety and Efficacy of Dexlansoprazole in Adolescents With Erosive Esophagitis

Frequently Asked Questions (FAQ)

Common questions about Dexlansoprazole (FAQ)


Q: How quickly should I expect Dexlansoprazole to start working for my acid reflux?

The official product information describes a unique Dual Delayed-Release (DDR) formulation that influences the onset of effect. This design releases the active ingredient in two phases: the first occurs about one to two hours after administration, followed by a second release within four to five hours. This aims to provide sustained acid-blocking activity over a full 24-hour period.

Q: What is the typical length of time people take Dexlansoprazole?

The length of time is determined by the specific condition being addressed. Regulatory documents define treatment durations such as up to 8 weeks for healing severe acid damage (erosive esophagitis), and shorter periods, such as 4 weeks, for symptomatic non-erosive GERD. Maintenance treatment for healed acid damage has been studied for periods up to 6 months.

Q: What is the longest course of treatment officially described for Dexlansoprazole?

Controlled clinical studies exploring the use of this medication for the maintenance of healed erosive esophagitis in adults did not extend beyond six months. The duration of use for an individual is outside the scope of the clinical trial data.

Q: Do studies suggest Dexlansoprazole is safe for long-term use?

Official regulatory warnings note that long-term daily use, defined as typically one year or longer, may be associated with potential risks, including an increased risk of bone fractures and low levels of magnesium or vitamin B12. Regulatory information highlights that the lowest effective dose and shortest duration appropriate to the condition are generally favored.

Q: What is the evidence regarding Dexlansoprazole and bone fractures?

Official safety information notes that long-term and high-dose PPI therapy may be associated with an increased risk of osteoporosis-related fractures. This includes potential fractures of the hip, wrist, or spine.

Q: What happens if a person forgets to take a dose of Dexlansoprazole?

Regulatory documents describe a procedure for managing a missed dose. This procedure outlines that if the next scheduled dose is imminent, the missed dose is generally skipped, and the individual should not take two doses at one time to make up for the missed amount.

Q: Does Dexlansoprazole come in an over-the-counter (OTC) version?

According to official regulatory status, dexlansoprazole is available only with a valid prescription from a healthcare provider.

Q: Are there any specific foods or drinks to avoid while taking Dexlansoprazole?

The medication can be taken without regard to food, meaning it can be administered before or after a meal. Official drug interaction information primarily lists other medications, and there are no specific common foods or drinks listed that must be avoided while taking this medicine.

Q: Is it true that Dexlansoprazole can affect vitamin B12 levels?

Official safety information notes that long-term daily use, typically longer than three years, of acid-suppressing medications may be associated with a malabsorption or deficiency of vitamin B12 (cyanocobalamin).

Q: Does Dexlansoprazole cause weight gain or weight loss?

The official adverse reactions list includes weight increase as an observation reported in some clinical trial settings. This observation is listed in the regulatory documents among other laboratory findings.

Q: Why is Dexlansoprazole sometimes described as a maintenance treatment?

Dexlansoprazole is officially approved for the 'maintenance of healed erosive esophagitis' (EE) as one of its three core indications. The use of the term is directly related to this specific, officially approved maintenance indication.

Q: Is there a generic version of Dexlansoprazole available?

Regulatory records from the FDA indicate that a generic formulation of dexlansoprazole has been approved and is available for use.

Q: Can taking Dexlansoprazole cause a dry mouth?

Official side effect information lists dry mouth as an adverse reaction that has been reported in postmarketing experience. This means the event has been observed, but its frequency is noted as not fully established or less common in controlled clinical trials.

Q: Can Dexlansoprazole cause changes in mood or anxiety?

Official safety information includes reports of mood or mental changes in postmarketing experience. These events have been reported after the drug was made available to the public, and their frequency is not established in controlled clinical trials.

Q: Does taking Dexlansoprazole affect the results of any common medical tests?

Yes, official warnings indicate that the medication may interfere with the results of certain medical tests, specifically tests for CgA (Chromogranin A) and secretin stimulation tests used to check for a specific type of tumor (gastrinoma). False positive urine screening tests for THC have also been reported.

Q: Is it safe to drink coffee while taking Dexlansoprazole?

Official drug interaction information focuses on other medicines and does not list specific common foods or drinks, such as coffee, that must be avoided. The medication can be taken without regard to food.

Q: Does Dexlansoprazole make it harder to absorb nutrients from food?

Long-term use of the medication may interfere with the body's ability to absorb vitamin B12 (cyanocobalamin) from food. This is an official warning related to the prolonged acid-reducing effect of this class of drugs.

Q: Is it normal to feel a bit nauseous when first starting Dexlansoprazole?

Official information classifies nausea as one of the most commonly reported adverse reactions observed in clinical trials. The classification as a commonly reported adverse reaction reflects its frequency in clinical trial data.

Q: Can men and women use Dexlansoprazole without a difference in effect?

Official regulatory documentation provides guidance for use and dose adjustments based on age and liver impairment. The documents do not list specific differences in use or dosage requirements for men versus women.

How should Dexlansoprazole be stored and disposed of?

How to Store and Dispose of Dexlansoprazole?

The storage and disposal requirements for Dexlansoprazole Delayed-Release Capsules are defined by official regulatory documentation to maintain the quality and integrity of the formulation.

Official Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F).
Protection Keep the medication protected from freezing, excess heat, direct light, and excess moisture.
Container Store in the container it came in, ensuring the container remains tightly closed.
Stability Note If the capsule is opened and the granules are mixed with food or liquid, the mixture must be taken immediately and cannot be saved for later use.
Safety Keep out of the sight and reach of children.

Official Disposal Instructions

To dispose of unused or expired medication, the preferred method is utilizing an authorized drug take-back program. The capsules must not be flushed down a toilet or sink drain. If a take-back option is unavailable, the capsules should be secured in a sealed container after mixing with an undesirable substance (such as dirt or used coffee grounds) before being discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dexlansoprazole found in:

A-Z Index: